Major Arthritis Trial Launched in Scotland
Scotland chosen to lead a £26m clinical trial for arthritis sufferers
SCOTLAND, UK, December 16, 2007-A £26m study of medicines to treat the pain of arthritis, which reinforces Scotland’s place as a leader in the delivery of major clinical trials, was launched today.
The SCOT Trial, (Standard Care versus Celecoxib Outcome Trial), will compare different types of treatment for arthritis-a series of conditions which affects around nine million people in the UK.
The trial compares traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac, with a newer NSAID called Celecoxib. Both types of NSAID are prescribed for the treatment of arthritis, but doctors want to know how the newer NSAID Celecoxib compares with the older NSAID in patients with arthritis in terms of long-term safety.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
